# China Pharma Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2014

- Company: [China Pharma Holdings, Inc.](/companies/cphi.md) (CIK 1106644)
- Form: 10-Q
- Filed: 2014-05-15
- Accepted by EDGAR: May 15, 2014, 09:30 ET
- Period: 2014-03-31
- Accession: 0001010549-14-000242
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1106644/000101054914000242/cphi10q033114.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1106644/000101054914000242/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-01-01 to 2014-03-31 | $7.1m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2014-01-01 to 2014-03-31 | $4.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2014-01-01 to 2014-03-31 | $2.7m | us-gaap:GrossProfit |
| Operating income | 3 months, 2014-01-01 to 2014-03-31 | −$2.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2014-01-01 to 2014-03-31 | $56.4k | us-gaap:InterestExpense |
| Income tax | 3 months, 2014-01-01 to 2014-03-31 | −$19.3k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2014-01-01 to 2014-03-31 | $50.4k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-01-01 to 2014-03-31 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2014-01-01 to 2014-03-31 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months, 2014-01-01 to 2014-03-31 | −$253.4k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2014-01-01 to 2014-03-31 | −$15.2k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2014-03-31 | $5.3m | us-gaap:Cash |
| Current assets | at 2014-03-31 | $77.9m | us-gaap:AssetsCurrent |
| Total assets | at 2014-03-31 | $154.3m | us-gaap:Assets |
| Current liabilities | at 2014-03-31 | $11.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-03-31 | $24.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2014-03-31 | $129.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 26,120 characters.

The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology, such as "anticipate", "believe", "expect", "plan", "intend", "seek", "estimate", "project", "could", "may" or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes to caution the readers of the forward-looking statements that any such statements that are contained in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors affecting our operations, markets, growth, services, products, licenses and other factors, some of which are described in this report and some of which are discussed in our other periodic filings with the Securities and Exchange Commission. These forward-looking statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events.

These risk factors should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral forward looking statements made in connection with this report that are attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

### Business Overview & Recent Developments

The Chinese Food and Drug Administration (“CFDA”) promulgated *Good Manufacturing Practices for Pharmaceutical Products* (2010 revised version) (the “new GMP”) on February 12, 2011, which became effective on March 1, 2011. The new GMP outlines the basic principles and standards for the manufacturing of pharmaceutical products and the management of quality controls in the manufacturing process in the PRC. Pursuant to those mandatory requirements, the upgrading of our two sterilization production lines - liquid injectable and dry powder injectable product lines were to be accomplished by the end of 2013. As of January 1, 2014, we had suspended such two production lines due to the failure to meet the GMP upgrading deadline. However, construction of the main building has been completed, and two new sterilization production lines have been installed, and are in testing and commissioning. We intend to submit the application for new GMP certificate in June 2014. We believe that the GMP upgrading will be accomplished in good quality and expect the new GMP certificate to be issued in approximately three to six months from our submission of the application.

Once our new facility receives a new GMP certificate and initiates production, we will begin upgrading our current existing old sterilization facility to meet new GMP standards and therefore expand our capacity in this product category.

The products in our pipeline have experienced delays. The CFDA has been improving its approval criteria and processes, resulting in additional supplemental materials and trials, higher cost, and longer approval time for certain applications across all the pharmaceutical products including all of our product types. We commenced leading formulation screening, new technology exploration and technical criteria improvement activities in 2013. We expect this new model will improve our exploration channels for the pipeline products.

The status of our pipeline products remains the same as we reported in our Annual Report on Form 10-K for the year ended December 31, 2013.

In the three months ended March 31, 2014, we continued to execute our prudent marketing strategy to implement a more stringent screening of existing and potential distributors and hospital customers in terms of speed of payment in order to gradually improve our trade turnover, especially in terms of the collection of our accounts receivable. This strategy temporarily impacts our sales in the current period by limiting our credit sales.

### Market Trends

The Chinese pharmaceutical industry has been a key contributor to the PRC’s economic growth. The Chinese pharmaceutical market reached CNY 926.1 billion in 2012 according to "*Medicine Blue Book: China Pharmaceutical Market Report (2012)*" (the “Blue Book”)published by the Chinese Academy of Social Sciences (CASS) on December 28, 2012. The compound growth rate of China's pharmaceutical market was over 20% from 2005 to 2010 and the Blue Book forecasts that it will continue its rapid expansion at an average rate of 12% from 2013 to 2020. The Blue Book pointed out that the Chinese pharmaceutical market is showing features of rapid expansion, fierce competition, low concentration, and is greatly influenced by government policies. The Blue Book further mentioned that the pharmaceutical market expansion was supported by increased demand for medicine associated with population aging, improved social welfare and residents’ enhanced purchasing power along with economic development.

The Healthcare Reform program announced by the Chinese government in late 2009 is having a significant impact on all healthcare related industries in China, including the pharmaceutical industry. Overall, the government plans to provide a basic, universal healthcare coverage to all citizens of China. We believe that the volume expansion will continue as the government subsidies to rural communities expand further. While pricing is generally set at the central government level, provincial government intervention has added complexity to the pricing-volume interaction. In addition to the Essential Drug List (EDL) products, we have also seen pricing pressure on most of the drugs we sell. While these changes have more impact on pharmaceutical distribution companies, manufacturers of pharmaceutical products are also affected. We believe the general implication is that gross margins for pharmaceutical products will continue to be under pressure for some time. That being said, we believe a pharmaceutical manufacturer with experienced management and the ability to react quickly to changes will survive in this environment.

### Results of Operations for the Three Months Ended March 31, 2014

China provides a unique opportunity to its pharmaceutical industry; however, real challenges remain: from compulsory GMP upgrading requirements and rising pricing pressure to extended regulatory review time for new medical production applications. Each of these challenges impacted our performance negatively in this period, causing us to experience a significant, but declining decrease in our financial results due to lower sales, increased costs related to new product development and continued challenges with the collection of accounts receivable prior to mandatory price reductions imposed by Healthcare Reform.

Net loss for the three months ended March 31, 2014 was $2.4 million, compared to net loss of $2.8 million for the three months ended March 31, 2013. Our net loss for the three months ended March 31, 2014 was mainly due to decrease in revenue, and increase in bad debt expense. This was partially offset by increases in gross profit due to higher margins, and there was no expense related to inventory obsolescence during the three months ended March 31, 2014.

### Revenue

Revenue decreased by 14% to $7.1 million for the three months ended March 31, 2014, as compared to $8.2 million for the three months ended March 31, 2013. The decrease in revenue slowed down compared to the prior quarters.

We suspended production of our dry powder injectable and liquid injectable products at our two old production lines as of January 1, 2014 due to the failure to meet the GMP upgrading deadline. In anticipation that this shutdown will affect our sales in 2014, we have gradually increased inventory levels of certain products in advance in order to support the sales demand for these products. We plan to start the upgrading of these two production lines once our new GMP facility starts operations.

Set forth below are our revenues by product category in millions USD for the three months ended March 31, 2014 and 2013:

| Product Category 2014 | Three Months Ended March 31 2013 |  | Net Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Anti-Viro/ Infection & Respiratory | $5.0 | $4.6 | $0.4 | 8% |
| CNS Cerebral & Cardio Vascular | $0.9 | $2.1 | ($1.2) | -57% |
| Digestive Diseases | $0.3 | $0.8 | ($0.5) | -64% |
| Other | $0.9 | $0.7 | $0.2 | 35% |

“Anti-Viro / Infection & Respiratory” category increased by $0.4 million to $5 million in the first quarter in 2014 compared to $4.6 million in the same period in 2013, which was mainly due to the sales increase of Cefaclor, which were affected primarily by market demand volatility.

The most significant revenue decrease in terms of dollar amount was in our “CNS Cerebral & Cardio Vascular” product category, which generated $0.9 million in sales revenue in the first quarter in 2014 compared to $2.1 million in the same period a year ago, a decrease of $1.2 million. The three months ended March 31, 2013 included sales of Buflomedil, sales of which were terminated in March of 2013 due to the CFDA notice for the termination of the production, sale and use of Buflomedil. The decrease in this category for the three months ended March 31, 2014 is primarily due to our termination of this product during the prior year comparable quarter.

Sales of the “Digestive Diseases” decreased by $0.5 million to $0.3 million in the first quarter in 2014 compared to $0.8 million in the same period in 2013, which was mainly due to the decrease in sales of Compound Ammonium Glycyrrhetate S and Tiopronin, which were affected primarily by market demand volatility.

Our “Other” category generated $0.9 million of sales in the first quarter in 2014, compared to $0.7 million in the same period last year, or an increase of $0.2 million.

In the three months ended March 31, 2014, revenue breakdown by product category showed some changes. Sales of the “Anti-Viro / Infection & Respiratory” products category represented 70% of total sales in the three months ended March 31, 2014, compared to 56% in the same period last year. The “CNS, Cerebral & Cardio Vascular” category represented 13% of total revenue in the three months ended March 31, 2014 and 26% in the same period last year. The “Digestive Diseases” category represented 4% of total revenue in three months ended March 31, 2014, compared to 10% in the same period last year. The “Other” category represented 13% and 10% of revenues in three months ended March 31, 2014 and 2013, respectively.

### Cost of Revenue

For the three months ended March 31, 2014, our cost of revenue was $4.4 million, or 63% of total revenue, which represented a decrease of $1.7 million from $6.1 million, or 74% of total revenue, in the first quarter of 2013. The decrease in cost of revenue in the first quarter of 2014 was mainly due to the decrease in purchasing prices of certain raw materials due to market fluctuation.

### Inventory Obsolescence

There was no inventory obsolescence for the three months ended March 31, 2014. For the three months ended March 31, 2013, we recorded $3.7 million of inventory obsolescence related to the discontinuation of Buflomedil production and sales pursuant to the prior year’s CFDA notice.

### Gross Profit (Loss) and Gross Margin

Gross profit for the three months ended March 31, 2014 was $2.7 million, an increase of $4.2 million, from gross loss of $1.6 million in the same period of 2013. Our gross profit margin in the first quarter of 2014 was 37% compared to gross loss margin of 19% in the same period 2013. The increase in gross margin was mainly due to the lack of inventory obsolescence in the first quarter 2014, decrease in purchasing prices of certain raw materials and increase in selling prices of certain products due to market fluctuation in this period. Going forward, we expect to see continued pricing pressures on most products, while new products could help to support overall gross margin once they are launched. We launched Candesartan in November, 2013 and started its marketing activities.

### Selling Expenses

Our selling expenses for the three months ended March 31, 2014 were $0.8 million, consistent with the $0.8 million in the same period last year. Selling expenses accounted for 12% of the total revenue in the first quarter 2014 compared to 10% in the same period in 2013. Due to many adjustments in our selling processes under healthcare reform policies, despite the decrease in sales, we still require comparable personnel and expenses to support our revenue and collection of accounts receivable.

### General and Administrative Expenses

Our general and administrative expenses for the three months ended March 31, 2014 were $0.4 million, a decrease of $0.2 million from $0.6 million in the same period 2013. General and administrative expenses accounted for 6% and 7% of our total revenues in the three months ended March 31, 2014 and 2013, respectively.

### Research and Development Expense

Our research and development expenses for the three months ended March 31, 2014 and 2013 were $0.4 million and $0.2 million, respectively. The increase in research and development expense was mainly due to our continued efforts to take a dominant position in the research activities relating to formulation screening, new technology exploration and technical criteria improvement.

### Bad Debt Expense (Benefit)

Our bad debt expenses for the three months ended March 31, 2014 were $3.3 million, and bad debt benefit was $0.1 million in the same period in 2013. The increase in bad debt expenses was mainly due to the increase in the accounts receivable with older age.

In general, our normal credit or payment terms extended to customers are 90 days. This has not changed in recent years. Due to the peculiarity of the Chinese pharmaceutical market environment, deferred payments to pharmaceutical companies by state-owned hospitals and local medicine distributors are a normal phenomenon. Our customers are primarily pharmaceutical distributors who sell to mostly government-backed hospitals. Therefore, the age of our receivables from our customers tends to be long. Although these customers typically pay after the due date of the receivables, since the majority of hospitals in China are backed by the government, management believes that the deferred payments from state-owned hospitals are secure and will eventually be collected.

The amount of accounts receivable that were past due (or the amount of accounts receivable that were more than 90 days old) was $39.5 million and $40.1 million as of March 31, 2014 and December 31, 2013, respectively. The following table illustrates our accounts receivable aging distribution in terms of percentage of total accounts receivable as of March 31, 2014 and December 31, 2013.

|  | March 31, 2014 | December 31, 2013 |
| --- | ---: | ---: |
| 1 - 90 Days | 6.8% | 8.0% |
| 90 - 180 Days | 6.0% | 7.4% |
| 180 - 360 Days | 14.0% | 23.3% |
| 360 - 720 Days | 51.4% | 61.3% |
| \> 720 Days | 21.8% | 0.0% |
| Total | 100.0% | 100.0% |

Our bad debt allowance estimate is currently the sum of 3.5% of accounts receivable that are less than 365 days old, 10% of accounts receivable that are between 365 days and 720 days old and 100% of accounts receivable that are greater than 720 days old.

We recognize bad debt expense per actual write-offs as well as the changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that of the previous period, we recognize a bad debt expense for the difference during the current period, and when the current allowance is lower than that of the previous period, we recognize a bad debt benefit for the difference. The allowance for doubtful accounts was $16.5 million and $13.3 million as of March 31, 2014 and December 31, 2013, respectively. The changes in the allowance for doubtful accounts during the three months ended March 31, 2014 and 2013 were as follows:

|  | For the Three Months Ended March 31, 2014 | 2013 |
| --- | ---: | ---: |
| Balance, Beginning of Period | $13,301,622 | $4,429,945 |
| Bad debt expense (benefit) | 3,308,129 | (119,930) |
| Foreign currency translation adjustment | (141,299) | 23,396 |
| Balance, End of Period | $16,468,452 | $4,333,411 |

### Loss from Operations

Our operating loss for the three months ended March 31, 2014 was $2.3 million, compared to operating loss of $3.0 million in the same period in 2013. The decrease of the operating loss was the primarily due to the inventory obsolescence recognized for the three months ended March 31, 2013, and the bad debt expense recognized for the three months ended March 31, 2014. This was partially offset by increases in gross profit due to overall higher margins during the three months ended March 31, 2014.

### Income Tax Expense (Benefit)

For the three months ended March 31, 2014 and 2013, our income tax rate was 15%. Income tax benefit was $0.2 million for the three months ended March 31, 2014, and income tax expense was $0.3 million for the three months ended March 31, 2013. The income taxes recognized for the three months ended March 31, 2014 and 2013 were related to changes in deferred tax assets and liabilities. We renewed our "National High-Tech Enterprise" status ("National HT Status") from the PRC government in the third quarter of 2013. With this designation, for the years ending December 31, 2014, 2015 and 2016, we will continue to enjoy a preferential tax rate of 15% which is notably lower than the statutory income tax rate of 25%.

### Net Loss

Net loss for three months ended March 31, 2014 was $2.4 million, compared to net loss of $2.8 million in the same period in 2013. The decrease of the net loss was primarily due to the inventory obsolescence recognized for the three months ended March 31, 2013, and the bad debt expense recognized for the three months ended March 31, 2014. This was partially offset by increases in gross profit due to overall higher margins during the three months ended March 31, 2014.

For the three months ended March 31, 2014, loss per basic and diluted common share was $0.05, compared to loss per basic and diluted share of $0.06 for the same period in 2013.

The number of basic and diluted weighted-average outstanding shares used to calculate loss per share was 43,579,557 for the three months ended March 31, 2014 and 2013, respectively.

### Liquidity and Capital Resources

Our principal sources of liquidity are cash generated from operations and short-term bank loans. Our cash and cash equivalents was $5.3 million, which represents 3% of our total assets as of March 31, 2014, as compared to $6.0 million, which represents 4% of our total assets as of December 31, 2013. All of the $5.3 million of cash and cash equivalents at March 31, 2014 is considered to be reinvested indefinitely in Helpson and is not expected to be available for payment of dividends, for other payments to our parent company or to its shareholders. As of March 31, 2014, we had a principal balance of $4.9 million in short-term bank loans. In addition, we entered into an eight-year construction loan facility with a bank on June 21, 2013. The total loan facility amount is RMB 80,000,000 (approximately $13 million), which had been fully utilized through May 7, 2014. The cash flow generated from operating activities is being used to fund the construction of our GMP upgrading project.

Based on our current operating plan, management believes that our cash provided by operations will be sufficient to meet our working capital needs and our anticipated capital expenditures, including expenditures for new formula acquisitions and GMP upgrading related construction and equipment, for the next twelve months. However, if events or circumstances change and we do not meet our operating plan as expected, we may be required to seek additional capital and/or to reduce certain discretionary spending, which could have a material adverse effect on our ability to achieve our business objectives. Notwithstanding the foregoing, we may seek additional financing as necessary for expansion purposes and when we believe market conditions are most advantageous, which may include debt and/or equity financing. There can be no assurance that any additional financing will be available on acceptable terms, if at all.

### Operating Activities

Net cash provided by operating activities was $2.5 million in the three months ended March 31, 2014 compared to $1.1 million for the same period in 2013. The decrease was mostly due to the decrease in inventory for the comparable periods.

At March 31, 2014, our accounts receivable was $42.3 million, a decrease of $2.8 million from $45.1 million at December 31, 2013. Our receivables decreased due to our enhanced collection efforts as well as the increased allowance for doubtful accounts at March 31, 2014 compared to December 31, 2013.

At March 31, 2014, total inventory was $22.9 million, a decrease of $1.8 million from $24.7 million at December 31, 2013. This decrease was mainly due to decreased purchases of raw materials for injectable products.

### Investing Activities

During the three months ended March 31, 2014, net cash used in investing activities was $3.8 million, compared to $0.4 million for the same period in 2013. The investment spending in the first quarter in 2014 was mainly for the GMP upgrading related construction and equipment.

### Financing Activities

There was $0.6 million cash flow provided from financing activities in the three months ended March 31, 2014 and there were no financing activities for the same period in 2013. The financing activities that occurred in 2014 were related to the construction loan facility described under the first paragraph under this section entitled “Liquidity and Capital Resources”.

According to relevant PRC laws, companies registered in the PRC, including our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax net income, as determined under accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach fifty percent (50%) of the companies’ registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends. As of March 31, 2014 and December 31, 2013 and 2012, the net assets of Helpson were $124,226,000 and $127,626,000, respectively. Due to the restriction on dividend distribution to overseas shareholders, the amount of Helpson’s net assets that were designated for general and statutory capital reserves, and thus could not be transferred to our parent company as cash dividends, were $8,182,770 and $8,182,770 (50% of registered capital) at March 31, 2014 and December 31, 2013, respectively. Since the amount that Helpson must set aside for the statutory surplus fund only accounts for 6.6% and 6.4%, respectively, of its total net assets, this reserve does not have a major impact on our liquidity. There were no allocations to the statutory surplus reserve accounts during the three months ended March 31, 2014.

The PRC government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of the PRC. Our businesses and assets are primarily denominated in RMB. All foreign exchange transactions take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People’s Bank of China. Approval of foreign currency payments by the People’s Bank of China or other regulatory institutions requires submitting a payment application form together with applicable invoices and signed contracts. These currency exchange control procedures imposed by the PRC government authorities may restrict the ability of Helpson, our PRC subsidiary, to transfer its net assets to our parent company through loans, advances or cash dividends.

### Off Balance Sheet Arrangements

As of March 31, 2014, we did not have any off-balance sheet arrangements.

### Commitments

At March 31, 2014 we were obligated to pay laboratories and others approximately $5.42 million over approximately the next four years upon completion of the various phases of contracts to provide CFDA production approval of medical formulas.

### Critical Accounting Policies

Management's discussion and analysis of its financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. Our financial statements reflect the selection and application of accounting policies which require management to make significant estimates and judgments. The discussion of our critical accounting policies contained in Note 1 to our consolidated financial statements, “Organization and Significant Accounting Policies”, is incorporated herein by reference.

## Market risk

As filed, 139 characters.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this item.

## Controls and procedures

As filed, 1,951 characters.

### Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and interim Chief Financial Officer, evaluated the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 (the “Exchange Act”) Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this quarterly report. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act (a) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (b) is accumulated and communicated to management, including our Chief Executive Officer and interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as described above. Based on this evaluation, our Chief Executive Officer and interim Chief Financial Officer concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective.

### Changes in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed May 15, 2014.
Source: SEC EDGAR, the filing index for accession 0001010549-14-000242. Last ingested by Listed: Nov 11, 2026, 00:23 ET. No prices; not investment advice.
